GeneDx (NASDAQ:WGS – Get Rating) and Sema4 (NASDAQ:SMFR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
This is a summary of recent recommendations and price targets for GeneDx and Sema4, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sema4 has a consensus target price of $2.67, suggesting a potential upside of 457.76%. Given Sema4’s higher possible upside, analysts plainly believe Sema4 is more favorable than GeneDx.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
56.0% of GeneDx shares are held by institutional investors. Comparatively, 56.0% of Sema4 shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
GeneDx has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Sema4 has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Earnings and Valuation
This table compares GeneDx and Sema4’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GeneDx||$212.20 million||0.87||-$245.39 million||($0.93)||-0.51|
|Sema4||$231.15 million||0.78||-$245.39 million||($0.93)||-0.51|
Sema4 is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.